Your browser doesn't support javascript.
loading
Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin.
Yu, Miao; Shankar, R Ravi; Zhang, Ruya; Zhang, Ye; Lin, Jianxin; O'Neill, Edward A; Chen, Guojuan; Liu, Shu; Tu, Yingmei; Engel, Samuel S.
Afiliação
  • Yu M; Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Beijing, China.
  • Shankar RR; Merck & Co., Inc, Kenilworth, New Jersey.
  • Zhang R; MSD China Holding Company, Shanghai, China.
  • Zhang Y; MSD China Holding Company, Shanghai, China.
  • Lin J; Merck & Co., Inc, Kenilworth, New Jersey.
  • O'Neill EA; Merck & Co., Inc, Kenilworth, New Jersey.
  • Chen G; MSD China Holding Company, Shanghai, China.
  • Liu S; Clinical Research, MSD China R&D Center, Beijing, China.
  • Tu Y; Clinical Research, MSD China R&D Center, Beijing, China.
  • Engel SS; Merck & Co., Inc, Kenilworth, New Jersey.
Diabetes Obes Metab ; 21(2): 408-411, 2019 02.
Article em En | MEDLINE | ID: mdl-30178570
ABSTRACT
To improve understanding of the safety and efficacy of adding sitagliptin to treatment of patients with type 2 diabetes taking premixed insulin, data from patients using premixed insulin ± metformin (screening HbA1c ≥7.5% and ≤11%) in either of two clinical trials in which sitagliptin 100 mg once-daily or placebo was added to various formulations of insulin treatment, were analysed. In both trials, insulin doses were to remain stable throughout the 24-week trial period. At week 24, the between-group difference (sitagliptin - placebo) in the least squares mean (95% confidence intervals) change from baseline in HbA1c in patients using premixed insulin was -0.43% (-0.58, -0.28), P <0.001. Adverse events were generally similar between the treatment groups. The incidence of symptomatic hypoglycaemia was slightly higher with sitagliptin, and the incidence of hypoglycaemia requiring medical attention was slightly higher with placebo; in both cases the difference was not statistically significant. The data from this pooled analysis confirm the utility of sitagliptin used in combination with premixed insulin in patients with type 2 diabetes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicemia / Diabetes Mellitus Tipo 2 / Fosfato de Sitagliptina / Insulina / Metformina Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicemia / Diabetes Mellitus Tipo 2 / Fosfato de Sitagliptina / Insulina / Metformina Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China